Investors

On Friday, May 20, 2022, the Board of Directors voted to wind down Genocea’s ongoing operations and terminate its employees except those employees deemed necessary to complete an orderly wind down. On May 23, 2022, we delivered formal notice to The Nasdaq Stock Market, Inc. that we intend to voluntarily delist our Common Stock from the Nasdaq Capital Market in connection with wind down and cessation of our operations. We plan to file a Form 25 with the Securities and Exchange Commission on or about June 2, 2022 to effect the voluntary delisting of the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended.

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

May 24, 2022
Genocea Announces Wind Down of Operations and Delisting From NASDAQ
CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that its Board of Directors voted to wind down the Company’s ongoing operations and terminate the Company’s READ MORE >
Apr 28, 2022
Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder READ MORE >
Apr 08, 2022
Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022
     GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with advanced solid tumors and progressive disease Dose escalation continues toward potentially more effective regimen Initial translational data corroborate clinical findings PLANET READ MORE >

Event and Presentations

Genocea presents regularly at top-tier scientific and investor conferences.

Events image
Past Event
Apr 12, 2022 2:15 PM EDT
21st Annual Needham Virtual Healthcare Conference
Listen to webcast
Events image
Past Event
Apr 8, 2022 4:30 PM EDT
Investor Webinar
Listen to webcast

Corporate Governance

The Board of Directors of Genocea Biosciences (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.

Financials and Filings

Contact Us